PA8578001A1 - Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas - Google Patents
Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicasInfo
- Publication number
- PA8578001A1 PA8578001A1 PA20038578001A PA8578001A PA8578001A1 PA 8578001 A1 PA8578001 A1 PA 8578001A1 PA 20038578001 A PA20038578001 A PA 20038578001A PA 8578001 A PA8578001 A PA 8578001A PA 8578001 A1 PA8578001 A1 PA 8578001A1
- Authority
- PA
- Panama
- Prior art keywords
- antineoplasic
- erb
- therapies
- therapeutic combinations
- quinasa
- Prior art date
Links
- 230000000118 anti-neoplastic effect Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000005865 ionizing radiation Effects 0.000 abstract 1
- 230000002427 irreversible effect Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40170502P | 2002-08-07 | 2002-08-07 | |
| US46224703P | 2003-04-11 | 2003-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8578001A1 true PA8578001A1 (es) | 2004-05-07 |
Family
ID=31720553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20038578001A PA8578001A1 (es) | 2002-08-07 | 2003-07-22 | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20040067942A1 (enExample) |
| EP (1) | EP1549320A1 (enExample) |
| JP (1) | JP2005538129A (enExample) |
| CN (1) | CN1674908A (enExample) |
| AR (1) | AR040792A1 (enExample) |
| AU (1) | AU2003249450A1 (enExample) |
| BR (1) | BR0313470A (enExample) |
| CA (1) | CA2494270A1 (enExample) |
| IL (1) | IL166423A0 (enExample) |
| MX (1) | MXPA05001430A (enExample) |
| NO (1) | NO20051170L (enExample) |
| PA (1) | PA8578001A1 (enExample) |
| PE (1) | PE20040990A1 (enExample) |
| PL (1) | PL375414A1 (enExample) |
| RU (1) | RU2005102836A (enExample) |
| TW (1) | TW200404532A (enExample) |
| WO (1) | WO2004014386A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| US7695731B2 (en) * | 2004-03-22 | 2010-04-13 | Cordis Corporation | Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury |
| US7910593B2 (en) | 2004-04-09 | 2011-03-22 | Chugai Seiyaku Kabushiki Kaisha | Water-soluble prodrugs |
| HRP20110958T1 (hr) | 2004-05-06 | 2012-01-31 | Warner-Lambert Company Llc | 4-fenilaminokinazolin-6-ilamidi |
| WO2005117916A1 (en) | 2004-06-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Treatment with cisplatin and an egfr-inhibitor |
| JP2008501652A (ja) * | 2004-06-03 | 2008-01-24 | エフ．ホフマン−ラ ロシュ アーゲー | ゲムシタビン及びｅｇｆｒインヒビターによる治療 |
| RU2006146625A (ru) * | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение иринотеканом (срт-11) и ингибитором рецептора эпидермального фактора роста (egfr) |
| MXPA06013952A (es) * | 2004-06-04 | 2007-02-08 | Smithkline Beecham Cork Ltd | Metodo para el tratamiento de cancer. |
| TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| US20080045589A1 (en) * | 2006-05-26 | 2008-02-21 | Susan Kelley | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer |
| RU2325199C2 (ru) * | 2006-06-20 | 2008-05-27 | Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) | Способ комбинированного лечения местно-распространенных форм рака шейки матки |
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| WO2009064738A2 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| CN103596592A (zh) * | 2011-05-06 | 2014-02-19 | 梅里麦克制药股份有限公司 | 用于预防包含抗ErbB3试剂的联合治疗中的毒性药物间相互作用的方法 |
| US20210275518A1 (en) * | 2020-03-06 | 2021-09-09 | Deciphera Pharmaceuticals, Llc | Methods of using rebastinib in the treatment of disorders |
| CN118576599A (zh) * | 2020-10-23 | 2024-09-03 | 和记黄埔医药（上海）有限公司 | 一种药物组合产品在制备用于治疗非小细胞肺癌的药物中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6287223B1 (en) * | 1997-04-11 | 2001-09-11 | Liechty, Ii Victor Jay | Dulling prevention for sharp cutting edge of blade-opening arrowhead blades when in a closed in-flight position |
| US6147107A (en) * | 1998-12-20 | 2000-11-14 | Virginia Commonwealth University | Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells |
| US6281223B1 (en) * | 1999-04-13 | 2001-08-28 | Supergen, Inc. | Radioenhanced camptothecin derivative cancer treatments |
| CA2436326C (en) * | 2001-01-09 | 2012-08-14 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
-
2003
- 2003-07-22 PA PA20038578001A patent/PA8578001A1/es unknown
- 2003-07-28 CN CNA038191180A patent/CN1674908A/zh active Pending
- 2003-07-28 WO PCT/IB2003/003388 patent/WO2004014386A1/en not_active Ceased
- 2003-07-28 EP EP03784371A patent/EP1549320A1/en not_active Withdrawn
- 2003-07-28 CA CA002494270A patent/CA2494270A1/en not_active Abandoned
- 2003-07-28 MX MXPA05001430A patent/MXPA05001430A/es unknown
- 2003-07-28 AU AU2003249450A patent/AU2003249450A1/en not_active Abandoned
- 2003-07-28 IL IL16642303A patent/IL166423A0/xx unknown
- 2003-07-28 PL PL03375414A patent/PL375414A1/xx not_active Application Discontinuation
- 2003-07-28 BR BR0313470-9A patent/BR0313470A/pt not_active IP Right Cessation
- 2003-07-28 RU RU2005102836/14A patent/RU2005102836A/ru not_active Application Discontinuation
- 2003-07-28 JP JP2004527183A patent/JP2005538129A/ja not_active Withdrawn
- 2003-08-01 US US10/632,281 patent/US20040067942A1/en not_active Abandoned
- 2003-08-04 PE PE2003000768A patent/PE20040990A1/es not_active Application Discontinuation
- 2003-08-05 AR AR20030102806A patent/AR040792A1/es unknown
- 2003-08-06 TW TW092121515A patent/TW200404532A/zh unknown
-
2005
- 2005-03-04 NO NO20051170A patent/NO20051170L/no unknown
-
2006
- 2006-08-14 US US11/464,249 patent/US20060293323A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060293323A1 (en) | 2006-12-28 |
| US20040067942A1 (en) | 2004-04-08 |
| NO20051170L (no) | 2005-05-06 |
| IL166423A0 (en) | 2006-01-15 |
| RU2005102836A (ru) | 2005-08-10 |
| MXPA05001430A (es) | 2005-06-06 |
| PE20040990A1 (es) | 2004-12-27 |
| EP1549320A1 (en) | 2005-07-06 |
| WO2004014386A1 (en) | 2004-02-19 |
| CA2494270A1 (en) | 2004-02-19 |
| AU2003249450A1 (en) | 2004-02-25 |
| JP2005538129A (ja) | 2005-12-15 |
| TW200404532A (en) | 2004-04-01 |
| PL375414A1 (en) | 2005-11-28 |
| CN1674908A (zh) | 2005-09-28 |
| BR0313470A (pt) | 2005-06-21 |
| AR040792A1 (es) | 2005-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048819A1 (es) | Metodos sinergicos y composiciones para el tratamiento del cancer | |
| PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| UY28287A1 (es) | Combinaciones para el tratamiento de enfermedades que impican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis | |
| CL2023003965A1 (es) | Inhibidores cdk2. | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| ECSP045407A (es) | Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf | |
| AR051968A1 (es) | Metodos y composiciones que utilizan inhibidores de jnk para el tratamiento y manejo de la lesion del sistema nervioso central | |
| UY31017A1 (es) | Uso de un inhibidor del factor &(alfa) de necrosis tumoral mas un antihistaminico para el tratamiento de la rinitis alérgica y la conjuntivitis alérgica. | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| BR0313470A (pt) | Combinações terapêuticas de inibidores erbb quinase e terapias antineoplásicas | |
| CL2007003523A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer | |
| NZ758548A (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| AR023400A1 (es) | Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores | |
| EA200801671A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| SV2003001493A (es) | Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion | |
| TW200631578A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury | |
| CY1111374T1 (el) | Ενωσεις που περιεχουν στροντιο για χρηση στην προληψη ή θεραπεια παθησεων νεκρωτικων οστων | |
| EP1628667A4 (en) | METHOD FOR TREATING DISEASES USING HSP90 INHIBITION AGENTS COMBINED WITH ANTIMITOTICS | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| BR112018013063A2 (pt) | combinação terapêutica inibidora de bromodomínio e proteína extra-terminal | |
| WO2005000212A3 (en) | Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors | |
| MX2024006934A (es) | Tratamiento del cancer con un inhibidor de la cinasa fgfr | |
| AR044452A1 (es) | Combinacion de un antagonista del receptor p2x7 y un inhibidor del factor de necrosis tumoral alfa | |
| MXPA05013478A (es) | Combinaciones terapeuticas. |